title: [Safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer].
abstract: OBJECTIVE
  To evaluate the safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer.
  
  
  METHODS
  A retrospective analysis of the clinical data of 49 patients with advanced pancreatic cancer, who did not receive radiotherapy and chemotherapy, were divided into two groups: the study group (25 cases), and control group (24 cases). Patients in the study group received gemcitabine 1 000 mg/m² via intravenous drip at the first and 8th days, and received S-1 80 mg/m², morning and evening (twice a day) for the first 14 days, and 21 days as a treatment cycle of chemotherapy.The control group was given GEMOX regimen: Gemcitabine 1 000 mg/m² via intravenous drip at the first and 8 days, and oxaliplatin 130 mg/m² via intravenous drip at the first day, and 21 d for a treatment cycle of chemotherapy. The efficacy and adverse reactions in patients of the study and control groups were observed and compared.
  
  
  RESULTS
  The efficiency of the study group was 32.0% and disease control rate was 72.0%. The efficiency of the control group was 25.0% and disease control rate was 58.3%. The differences between the two groups were statistically not significant (P > 0.05 for all). The clinical benefit rate in the study group and control group were 80.0% and 50.0%, respectively, showing a significant difference (P < 0.05). The median survival time was 9.7 months in patients of the study group and 9.0 months in the control group, with a significant difference (P < 0.05). The drug toxicity was well tolerated in both groups, and no chemotherapy-related death occurred. The major adverse reactions were myelosuppression and digestive tract reactions, and the adverse reactions in the study group were lower than those in the control group.
  
  
  CONCLUSIONS
  Gemcitabine combined with S-1 is effective and safe in the treatment of advanced pancreatic cancer, with less side effects, and can be tolerated by the patients.
authors.affiliation: Department of Oncology, General Hospital of the Panzhihua Steel Group, Panzhihua 617023, China; Email: 904631265@qq.com.
authors.forename: Yingqiang
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Oncology, General Hospital of the Panzhihua Steel Group, Panzhihua 617023, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Zhong
authors.affiliation: Department of Oncology, General Hospital of the Panzhihua Steel Group, Panzhihua 617023, China.
authors.forename: Ping
authors.initials: P
authors.lastname: He
authors.affiliation: Department of Oncology, General Hospital of the Panzhihua Steel Group, Panzhihua 617023, China.
authors.forename: Lianxi
authors.initials: L
authors.lastname: Zheng
authors.affiliation: Department of Oncology, General Hospital of the Panzhihua Steel Group, Panzhihua 617023, China.
authors.forename: Ke
authors.initials: K
authors.lastname: Yang
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004338:Drug Combinations; D006801:Humans; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine